Tanaka H - Search Results

1

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.

Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H. Taniguchi Y, et al. Among authors: tanaka h. Clin Cancer Res. 2022 Oct 14;28(20):4402-4409. doi: 10.1158/1078-0432.CCR-22-1687. Clin Cancer Res. 2022. PMID: 35980349 Free PMC article. Clinical Trial.

2

Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Horiike A, Yamamoto N, Tanaka H, Yanagitani N, Kudo K, Ohyanagi F, Ono A, Naito T, Murakami H, Horai T, Nishio M. Horiike A, et al. Among authors: tanaka h. Anticancer Res. 2014 Apr;34(4):1975-81. Anticancer Res. 2014. PMID: 24692734 Clinical Trial.

3

Plasma homocysteine levels and hematological toxicity in NSCLC patients after the first cycle of pemetrexed under folate supplementation.

Tanaka H, Horiike A, Sakatani T, Saito R, Yanagitani N, Kudo K, Ohyanagi F, Horai T, Nishio M. Tanaka H, et al. Anticancer Drugs. 2015 Jun;26(5):573-8. doi: 10.1097/CAD.0000000000000220. Anticancer Drugs. 2015. PMID: 25714250

4

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Tanaka H, Taima K, Tanaka Y, Itoga M, Ishioka Y, Nakagawa H, Baba K, Hasegawa Y, Takanashi S, Tasaka S. Tanaka H, et al. Among authors: tanaka y. Med Oncol. 2018 Feb 8;35(3):34. doi: 10.1007/s12032-018-1098-3. Med Oncol. 2018. PMID: 29423683 Free PMC article. Clinical Trial.

5

Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study).

Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, Nakagawa H, Takahashi N, Bessho A, Soejima K, Kishi K, Togashi A, Kanai Y, Ueda K, Horimoto K, Matsutani N, Seki N. Okuma Y, et al. Among authors: tanaka h. Thorac Cancer. 2019 Feb;10(2):395-400. doi: 10.1111/1759-7714.12923. Epub 2018 Dec 8. Thorac Cancer. 2019. PMID: 30536780 Free PMC article.

6

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.

Baba K, Tanaka H, Sakamoto H, Shiratori T, Tsuchiya J, Ishioka Y, Itoga M, Taima K, Tasaka S. Baba K, et al. Among authors: tanaka h. Thorac Cancer. 2019 Feb;10(2):369-372. doi: 10.1111/1759-7714.12939. Epub 2019 Jan 2. Thorac Cancer. 2019. PMID: 30600919 Free PMC article.

7

The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.

Sakamoto H, Tanaka H, Shiratori T, Baba K, Ishioka Y, Itoga M, Taima K, Hasegawa Y, Takanashi S, Tasaka S. Sakamoto H, et al. Among authors: tanaka h. Mol Clin Oncol. 2019 Jun;10(6):610-614. doi: 10.3892/mco.2019.1838. Epub 2019 Apr 3. Mol Clin Oncol. 2019. PMID: 31031976 Free PMC article.

8

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.

Tanaka H, Taima K, Itoga M, Ishioka Y, Baba K, Shiratori T, Sakamoto H, Tsuchiya J, Nakagawa H, Hasegawa Y, Yasugahira H, Okudera K, Takanashi S, Tasaka S. Tanaka H, et al. Med Oncol. 2019 May 14;36(6):57. doi: 10.1007/s12032-019-1278-9. Med Oncol. 2019. PMID: 31089973

9

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol.

Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, Mouri T, Tanaka H, Kimura M, Imai H, Mizukami T, Imoto A, Kondoh C, Shiotsu S, Okuyama H, Ueno M, Takahashi T, Tsuji T, Aragane H, Inui A, Higashiguchi T, Takayama K. Miura S, et al. Among authors: tanaka h. BMC Cancer. 2019 May 31;19(1):528. doi: 10.1186/s12885-019-5762-6. BMC Cancer. 2019. PMID: 31151425 Free PMC article.

10

A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).

Asahina H, Oizumi S, Takamura K, Harada T, Harada M, Yokouchi H, Kanazawa K, Fujita Y, Kojima T, Sugaya F, Tanaka H, Honda R, Kikuchi E, Ikari T, Ogi T, Shimizu K, Suzuki M, Konno S, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Asahina H, et al. Among authors: tanaka h. Lung Cancer. 2019 Dec;138:65-71. doi: 10.1016/j.lungcan.2019.09.020. Epub 2019 Sep 30. Lung Cancer. 2019. PMID: 31654836 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15,002 results

Search Page